Clinical Trials Logo

Clinical Trial Summary

This phase II trial studies how well pembrolizumab and sunitinib malate work in treating participants with thymic cancer that has spread to other places in the body or cannot be removed by surgery and does not respond to treatment. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and sunitinib malate may work better in treating thymic cancer.


Clinical Trial Description

PRIMARY OBJECTIVES: I. To evaluate the efficacy of pembrolizumab and sunitinib malate (sunitinib) for the treatment of patients with thymic carcinoma that have progressed on prior platinum based chemotherapy as measured by objective response rate. SECONDARY OBJECTIVES: I. To evaluate the safety profile and toxicity of combination pembrolizumab and sunitinib malate as per Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4.0. II. To evaluate the progression free survival (PFS) and overall survival (OS) of patients treated with combination pembrolizumab and sunitinib. EXPLORATORY OBJECTIVES: I. To determine objective response rate (ORR), PFS, and OS by PD-L1 expression > 50% tumor proportion score (TPS) (by 22C3 assay) II. To determine whether sunitinib treatment leads to increase in PD-L1 expression and tumor infiltrating lymphocytes and decrease in myeloid-derived suppressor cells (MDSC) in both tumor and peripheral blood. OUTLINE: Participants receive pembrolizumab intravenously (IV) over 30 minutes on day 1 and sunitinib malate orally (PO) daily on days 1-14. Courses repeat every 21 days for 24 months in the absence of disease progression or unacceptable toxicity. After completion of the study treatment, participants are followed up for 30 days, every 6 weeks for 1 year, and every 9 or 12 weeks thereafter. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03463460
Study type Interventional
Source Ohio State University Comprehensive Cancer Center
Contact
Status Suspended
Phase Phase 2
Start date June 19, 2018
Completion date December 31, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT06019468 - Neoadjuvant Treatment For Locally Advanced Thymic Cancer Phase 2
Terminated NCT00818090 - Paclitaxel and Cisplatin for Thymic Neoplasm Phase 2
Completed NCT02623127 - A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma Phase 2
Active, not recruiting NCT03921671 - Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT) Phase 2
Active, not recruiting NCT02364076 - Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma Phase 2
Terminated NCT01100944 - A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies Phase 1/Phase 2
Recruiting NCT03449173 - Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial) Phase 2
Recruiting NCT03556228 - Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma Phase 1
Completed NCT01364727 - A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies Phase 2
Completed NCT00010257 - Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma Phase 2
Completed NCT04430842 - Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S Phase 1
Active, not recruiting NCT03583086 - Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors Phase 1/Phase 2
Completed NCT03517488 - A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors Phase 1
Completed NCT00198133 - Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma Phase 2
Recruiting NCT03170804 - Genomic Profiling of Nodular Thyroid Disease and Thyroid Cancer N/A
Recruiting NCT05667948 - Molecular Analysis and Treatment Options of Thymic Malignancies
Terminated NCT01011439 - Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma Phase 2
Terminated NCT01143545 - Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas Phase 1
Completed NCT02307500 - Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy Phase 2
Active, not recruiting NCT01025089 - Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma Phase 2